Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03942211 · ClinicalTrials.gov registry record · Phase 2
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
A Phase 2 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03942211 is a Phase 2 study that was terminated before completion, run by Actelion. The registered enrollment target is 10 participants.
The verdict
NCT03942211, a Phase 2 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH). The aim of the present study is to investigate whether selexipag could be helpful to treat patients with another form of PH called sarcoidosis-associated pulmonary hypertension (SAPH).
Interventions
- DRUG Placebo
- DRUG Selexipag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-02-26 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03942211
The ClinicalTrials.gov registry entry for NCT03942211 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03942211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03942211 about?
NCT03942211 is a clinical study titled "A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag". Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH). The aim of the present study is to investigate whether selexipag could be helpful to treat patients with another form of ...
What is the current status of trial NCT03942211?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-02-26. Estimated completion is 2023-04-19.
What interventions are being tested in trial NCT03942211?
The interventions under investigation include: Placebo (DRUG), Selexipag (DRUG).
Who is sponsoring clinical trial NCT03942211?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.